Related Experiment Video
Updated: Jun 25, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Clopidogrel-Induced Interstitial Lung Disease: A Case Report
Jin An1, Seung Hwan Lee2, Boksoon Chang1
1Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Insights
Clopidogrel, a common antiplatelet medication, can rarely cause interstitial lung disease. Prompt withdrawal of clopidogrel and steroid treatment led to patient recovery, highlighting the importance of recognizing this adverse effect.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Dual antiplatelet therapy with aspirin and clopidogrel is crucial for preventing recurrent ischemic events in patients with intracranial arterial stenosis.
- Clopidogrel, while effective, carries a risk of adverse effects, primarily hemorrhagic complications.
- Interstitial lung disease (ILD) is a recognized, albeit rare, potential adverse reaction to clopidogrel.
Observation:
- A 79-year-old female patient on dual antiplatelet therapy presented with acute dyspnea.
- Chest CT revealed bilateral peribronchial ground-glass opacity and reticulation, with negative infectious workup.
- Symptoms improved significantly after clopidogrel withdrawal and initiation of steroid therapy.
Findings:
- The patient's presentation and subsequent recovery strongly suggest clopidogrel-induced interstitial lung disease.
- This case highlights a rare but serious pulmonary complication associated with clopidogrel use.
- Early recognition and management, including drug discontinuation and corticosteroid administration, are key to favorable outcomes.
Implications:
- Clinicians should consider clopidogrel-induced ILD in patients presenting with unexplained pulmonary symptoms while on this medication.
- Awareness of this rare adverse effect is critical for timely diagnosis and appropriate patient management.
- This case underscores the need for vigilant monitoring of potential drug-induced lung injuries in clinical practice.
Abstract:
In patients, with cerebral infarction resulting from intracranial arterial stenosis, the combined administration of clopidogrel and aspirin may be needed for to prevent subsequent ischemic attacks. Clopidogrel has an inevitable adverse effect profile, and the most common complications are related to hemorrhagic propensity. A 79-year-old female patient had used aspirin (100 mg/day) for cerebral infarction and then a dual antiplatelet regimen of aspirin and clopidogrel (75 mg/day) because of severe stenosis in both anterior cerebral arteries. Two weeks later, the patient presented with dyspnea started 3 days ago, which had worsened in the last 24 hours. Chest computed tomography on admission showed symmetric peribronchial ground-glass opacity with reticulation in both lungs. Microorganism tests, including serology and bronchoalveolar lavage for infection, were all negative. Clopidogrel was withdrawn because of suspected clopidogrel-induced interstitial lung disease, and steroid treatment was initiated. Clinical signs and chest radiographs improved after steroid treatment, and she was discharged on day 21 of admission. This case report shows that clopidogrel can induce interstitial lung disease as a rare complication and underscores the importance of recognizing this adverse effect in clinical practice.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease-I: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Pulmonary Embolism I: Introduction

